A disruptive technology to tackle brain cancer and glioblastoma
News
Hemerion strengthens its management to accelerate clinical development
After receiving several positive feedback from European and US health agencies, Hemerion is preparing to scale up its teams for the implementation of a pivotal clinical trial, the last step… ...
Positive FDA feedback on Hemerion’s clinical strategy for glioblastoma
The Food and Drug Administration (FDA) has issued a positive feedback on Hemerion’s clinical strategy following a Type C Meeting held in November 2025. The U.S. health authority confirmed the… ...
Hemerion’s breakthrough glioblastoma approach featured in new peer-reviewed case report
A newly published case report in the renowned Journal of Neuro-Oncology Discovery provides compelling clinical evidence of the feasibility, safety and workflow integration of the Pentalafen®/Heliance® combination therapy in treating… ...
Stay tuned to our clinical advances
They talk about us
